PL2170403T3 - Kompozycje i sposoby hamowania ekspresji genów proapoptotycznych - Google Patents

Kompozycje i sposoby hamowania ekspresji genów proapoptotycznych

Info

Publication number
PL2170403T3
PL2170403T3 PL08763631T PL08763631T PL2170403T3 PL 2170403 T3 PL2170403 T3 PL 2170403T3 PL 08763631 T PL08763631 T PL 08763631T PL 08763631 T PL08763631 T PL 08763631T PL 2170403 T3 PL2170403 T3 PL 2170403T3
Authority
PL
Poland
Prior art keywords
pro
compositions
methods
inhibiting expression
apoptotic genes
Prior art date
Application number
PL08763631T
Other languages
English (en)
Inventor
Hagar Kalinski
Igor Mett
Elena Feinstein
Shai Dr Erlich
Original Assignee
Quark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Pharmaceuticals Inc filed Critical Quark Pharmaceuticals Inc
Publication of PL2170403T3 publication Critical patent/PL2170403T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL08763631T 2007-06-27 2008-06-26 Kompozycje i sposoby hamowania ekspresji genów proapoptotycznych PL2170403T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93731807P 2007-06-27 2007-06-27
US96432507P 2007-08-10 2007-08-10
PCT/IL2008/000874 WO2009001359A2 (en) 2007-06-27 2008-06-26 Compositions and methods for inhibiting expression of pro-apoptotic genes
EP08763631.2A EP2170403B1 (en) 2007-06-27 2008-06-26 Compositions and methods for inhibiting expression of pro-apoptotic genes

Publications (1)

Publication Number Publication Date
PL2170403T3 true PL2170403T3 (pl) 2014-09-30

Family

ID=40186122

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08763631T PL2170403T3 (pl) 2007-06-27 2008-06-26 Kompozycje i sposoby hamowania ekspresji genów proapoptotycznych

Country Status (9)

Country Link
US (1) US8785408B2 (pl)
EP (1) EP2170403B1 (pl)
DK (1) DK2170403T3 (pl)
ES (1) ES2474176T3 (pl)
HR (1) HRP20140522T1 (pl)
PL (1) PL2170403T3 (pl)
PT (1) PT2170403E (pl)
SI (1) SI2170403T1 (pl)
WO (1) WO2009001359A2 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
JP4991547B2 (ja) 2004-09-28 2012-08-01 クアーク・ファーマスーティカルス、インコーポレイテッド 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US8362229B2 (en) 2006-02-08 2013-01-29 Quark Pharmaceuticals, Inc. Tandem siRNAS
SI2170403T1 (sl) 2007-06-27 2014-07-31 Quark Pharmaceuticals, Inc. Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov
US20110288155A1 (en) 2008-12-18 2011-11-24 Elena Feinstein Sirna compounds and methods of use thereof
EP2440214A4 (en) 2009-06-08 2013-07-31 Quark Pharmaceuticals Inc METHOD FOR THE TREATMENT OF CHRONIC KIDNEY DISEASES
EP2322656A1 (en) * 2009-11-17 2011-05-18 Centre National de la Recherche Scientifique (C.N.R.S) Methods for diagnosing skin diseases
TW201124160A (en) 2009-11-26 2011-07-16 Quark Pharmaceuticals Inc SiRNA compounds comprising terminal substitutions
WO2011072091A1 (en) 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
CA2818024C (en) 2010-12-06 2019-09-24 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
US11058708B2 (en) * 2011-09-19 2021-07-13 Sweyshen Chen RNA interference of galectin-3 expression and methods of use thereof
EP2773758B1 (en) 2011-11-03 2017-06-07 Quark Pharmaceuticals, Inc. Compositions for use in neuroprotection
US20140323549A1 (en) 2011-11-08 2014-10-30 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
US9295631B2 (en) 2012-02-13 2016-03-29 Conopco, Inc. Skin lightening composition
EP2895608B1 (en) 2012-09-12 2018-12-05 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof
DK3149172T3 (en) 2014-05-29 2018-08-20 Quark Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE PREVENTION OF ISKEMIC REPERFUSION LESSON IN BODIES
EP3270881B1 (en) 2015-03-20 2018-12-26 Unilever PLC, a company registered in England and Wales under company no. 41424 of Antiperspirant composition
CA3013799A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Methods of modulating keap1
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
CN108904517B (zh) * 2018-06-20 2020-08-21 军事科学院军事医学研究院环境医学与作业医学研究所 抑制Sestrin2蛋白表达的siRNA在制备抗肺鳞状上皮癌药物中的应用
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
US11859213B2 (en) 2019-05-16 2024-01-02 Regents Of The University Of Minnesota Development of superior chimerism by hiPSC engineering and embryo aggregation
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021231646A1 (en) * 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
WO2021231644A1 (en) * 2020-05-13 2021-11-18 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
PE20231096A1 (es) 2020-08-25 2023-07-18 Lilly Co Eli Polimorfos de un inhibidor de ssao
EP4364728A4 (en) * 2021-06-30 2025-07-02 Primoris Therapeutics Co Ltd PHARMACEUTICAL COMPOSITION CONTAINING NATURAL OR ARTIFICIAL CELL-DERIVED NANOVESICLES LOADED WITH AN ANTISENSE OLIGONUCLEOTIDE-BASED DRUG
WO2024104663A1 (en) 2022-11-16 2024-05-23 Unilever Ip Holdings B.V. Method of reducing malodour

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2463774A1 (fr) 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3526287A1 (de) * 1985-07-23 1987-02-05 Fichtel & Sachs Ag Rillenlaeufe fuer visko-luefterkupplung
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
CA2028756A1 (en) 1989-11-24 1991-05-25 Alfons H. M. Raeymaekers Immunostimulating 6-aryl-5,6-dihydro-imidazo[2,1-b]thiazole derivatives
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US20080119427A1 (en) 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5849774A (en) 1996-07-03 1998-12-15 University Of Pittsburgh Treatment of sepsis-induced acute renal failure
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999055910A1 (en) 1998-04-24 1999-11-04 Arizona Board Of Regents Method of inducing apoptosis in a target cell
AU771579B2 (en) 1998-10-26 2004-03-25 Avi Biopharma, Inc. p53 antisense agent and method
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
EP1143943B1 (en) 1999-01-29 2007-12-12 The Board Of Trustees Of The University Of Illinois USE OF p53 INHIBITORS FOR THE TREATMENT OF SIDE EFFECTS OF CANCER THERAPY
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
JP2004532616A (ja) 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖ｒｎａ仲介遺伝子抑制
US20050260620A1 (en) 2001-05-18 2005-11-24 Sirna Therapeutics, Inc. RNA interference mediated inhibition of retinolblastoma (RBI) gene expression using short interfering nucleic acid (siNA)
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
EP1478656B1 (en) 2002-02-01 2009-09-16 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
AU2003249012A1 (en) 2002-09-30 2004-04-23 Japan As Represented By The President Of The University Of Tokyo Genes and polypeptides relating to human myeloid leukemia
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
JP2006522158A (ja) 2003-04-03 2006-09-28 アルナイラム ファーマシューティカルズ インコーポレイテッド ｉＲＮＡ複合体
CA2528012C (en) 2003-06-02 2015-11-24 University Of Massachusetts Methods and compositions for controlling efficacy of rna silencing
WO2005062937A2 (en) 2003-12-22 2005-07-14 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
US20060024278A1 (en) 2004-01-23 2006-02-02 The General Hospital Corporation Methods and products related to the production of inner ear hair cells
US7452547B2 (en) * 2004-03-31 2008-11-18 Johnson&Johnson Consumer Co., Inc. Product for treating the skin comprising a polyamine microcapsule wall and a skin lightening agent
CA2565701A1 (en) 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
IL162276A0 (en) 2004-06-01 2005-11-20 Hadasit Med Res Service Nucleic acid molecules as heparanase potent inhibitors, compositions and methods of use thereof
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
NZ553162A (en) 2004-08-16 2010-03-26 Quark Biotech Inc Double stranded siRNA compounds that inhibit RRTP801
JP4991547B2 (ja) 2004-09-28 2012-08-01 クアーク・ファーマスーティカルス、インコーポレイテッド 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法
WO2006038574A1 (ja) 2004-10-04 2006-04-13 Sharp Kabushiki Kaisha 表示装置および電子機器
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US20070259827A1 (en) 2006-01-25 2007-11-08 University Of Massachusetts Compositions and methods for enhancing discriminatory RNA interference
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
RU2469090C2 (ru) 2006-05-19 2012-12-10 Алькон Рисерч, Лтд. iPHK-ОПОСРЕДОВАННОЕ ИНГИБИРОВАНИЕ СВЯЗАННЫХ С ФАКТОРОМ НЕКРОЗА ОПУХОЛИ АЛЬФА СОСТОЯНИЙ
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
SI2170403T1 (sl) 2007-06-27 2014-07-31 Quark Pharmaceuticals, Inc. Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov
WO2009023025A1 (en) 2007-08-13 2009-02-19 Board Of Trustees Of Southern Illinois University Methods for treatment and prevention of ototoxicity by sirna
US8431692B2 (en) 2008-06-06 2013-04-30 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders

Also Published As

Publication number Publication date
US8785408B2 (en) 2014-07-22
US20100222409A1 (en) 2010-09-02
SI2170403T1 (sl) 2014-07-31
WO2009001359A3 (en) 2010-03-04
HRP20140522T1 (hr) 2014-08-15
ES2474176T3 (es) 2014-07-08
PT2170403E (pt) 2014-07-17
EP2170403A4 (en) 2011-06-15
DK2170403T3 (da) 2014-06-16
EP2170403B1 (en) 2014-04-16
WO2009001359A2 (en) 2008-12-31
EP2170403A2 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
EP2170403A4 (en) COMPOSITIONS AND METHODS FOR SUPPRESSING THE EXPRESSION OF PRO-APOPTOTIC GENES
HUS1900009I1 (hu) Új vegyületek és készítmények, továbbá alkalmazási eljárásaik
EP2066687A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HAMP GENE
PT2470656E (pt) Composição para inibir expressão de gene e suas utilizações
IL250678A0 (en) Compounds and methods for repressing pcsk9 gene expression
ZA200908481B (en) Compositions and methods for altering gene expression
IL194419A0 (en) Compositions and methods for inhibiting expression of eg5 gene
ZA201103424B (en) Compositions and methods for inhibiting expression of factor vii genes
IL245172A0 (en) Pharmaceutical preparations and methods for transferring them related to them
EP1941059A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE HUNTINGTIN GENE
ZA200908342B (en) Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
EP2334185A4 (en) COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
IL202184A0 (en) Methods and compositions for increased transgene expression
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
EP2112931A4 (en) METHOD AND COMPOSITIONS FOR THE TRANSDERMAL RELEASE OF NUCLEOTIDES
IL238404A0 (en) Preparations and methods to prevent influenza
EP2370415A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING THE JAK PATH
EP2018443A4 (en) COMPOSITIONS AND METHODS INHIBITING EXPRESSION OF IKK-B GENE
IL204945A0 (en) Compositions and methods for inhibiting tumor progression
IL201766A0 (en) Compositions of (-)-e-10-oh-nt and methods for their synthesis and use
EP2307558A4 (en) COMPOSITIONS AND PROCEDURES FOR THE PROTECTION OF NUCLEOPHILER GROUPS
IL213147A0 (en) Compositions and methods for inhibiting expression of ptp1b genes
HK1146545A (en) Compositions and methods for inhibiting expression of factor vii gene
GB0803464D0 (en) Methods and compositions